POLITECNICO DI TORINO Repository ISTITUZIONALE

Effects of mutations and immunogenicity on outcomes of anti-cancer therapies for secondary lesions

Original

Effects of mutations and immunogenicity on outcomes of anti-cancer therapies for secondary lesions / Piretto, Elena; Delitala, Marcello; Kim, Peter S.; Frascoli, Federico. - In: MATHEMATICAL BIOSCIENCES. - ISSN 0025-5564. - ELETTRONICO. - 315:(2019), p. 108238. [10.1016/j.mbs.2019.108238]

Availability: This version is available at: 11583/2747372 since: 2020-05-13T11:18:37Z

Publisher: Elsevier

Published DOI:10.1016/j.mbs.2019.108238

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

Effects of mutations and immunogenicity on outcomes of anti-cancer therapies for secondary lesions

Elena Piretto^{a,b,d}, Marcello Delitala^a, Peter S. Kim^c, Federico Frascoli^{d,*}

 ^aDepartment of Mathematical Sciences, Politecnico di Torino, Turin, Italy
 ^bDepartment of Mathematics, Universitá di Torino, Turin, Italy
 ^cSchool of Mathematics and Statistics, University of Sydney, Sydney, New South Wales, Australia
 ^dDepartment of Mathematics, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, Victoria, Australia

Abstract

Cancer development is driven by mutations and selective forces, including the action of the immune system and interspecific competition. When administered to patients, anti-cancer therapies affect the development and dynamics of tumours, possibly with various degrees of resistance due to immunoediting and microenvironment. Tumours are able to express a variety of competing phenotypes with different attributes and thus respond differently to various anti-cancer therapies.

In this paper, a mathematical framework incorporating a system of delay differential equations for the immune system activation cycle and an agent-based approach for tumour-immune interaction is presented. The focus is on those metastatic, secondary solid lesions that are still undetected and non-vascularised.

By using available experimental data, we analyse the effects of combination therapies on these lesions and investigate the role of mutations on the rates of success of common treatments. Findings show that mutations, growth properties and immunoediting influence therapies' outcomes in nonlinear and complex ways, affecting cancer lesion morphologies, phenotypical compositions and overall proliferation patterns. Cascade effects

Preprint submitted to Mathematical Biosciences

^{*}Corresponding author

Email address: ffrascoli@gmail.com (Federico Frascoli)

on final outcomes for secondary lesions are also investigated, showing that actions on primary lesions could sometimes result in unexpected clearances of secondary tumours. This outcome is strongly dependent on the clonal composition of the primary and secondary masses and is shown to allow, in some cases, the control of the disease for years.

Keywords: secondary lesions, immune response, combination therapies, tumour morphology

1 1. Introduction

Cancer is a generic definition of a disease that, among its typical features, is driven by dynamic alterations in the genome [1]. These microscopic changes not only give birth to a variety of different types of cancer at the macroscopic scale, but can also lead to heterogeneity within the same cancer tissue: tumour phenotypes undergo clonal expansion and genetic diversification, promoting natural selection mechanisms that favor cell clones with advantageous characteristics [2, 3].

Alterations in the DNA of the cell, such as inclusions of copy number g aberrations and point mutations, occur early during the neoplastic trans-10 formation and usually before any possible clinical detection [4]. The step-11 12 wise accumulation of driver mutations may confer survival advantages in relation to the particular environment in which they are embedded and 13 may be accelerated by so-called selective sweeps [5]. Furthermore, al-14 though the immune system routinely recognises and kills any dangerous 15 host including cancer, mutations can provide cancer cells with the ability 16 to avoid detection or immuno-suppress the environment, advantaging tu-17 mour progression or preventing eradication [1]. Processes involving mu-18 tations, cell growth and immune surveillance cumulatively result in the 19 emergence of different cancer populations integrated in an environment 20 made up of healthy tissue, immune cells and stroma [6, 7]. 21

Understanding how these complex interactions shape and influence each other is one of the greatest challenges in current medical biosciences. For example, morphology is known to be strongly sensitive to tumour adaptation to the environment (e.g. the lack of nutrients, oxygen, space) and by the combined action of immune response and existing anti-cancer therapies [8] such as chemotherapy, radiotherapy, immune-boosting and so on. In the last quarter of century, a number of diverse contributions

have been proposed from the biomathematical community to shed light 29 on some of these complex interaction mechanisms. Several mathemati-30 cal models have been advanced using the framework of population dy-31 namics, with tumour immune interactions considered, for example, in 32 Ref. [9, 10] and cancer mutations in Ref. [11]. Other works have involved 33 a discrete Cellular Potts approach [12] or different degrees of hybrid mod-34 elling [13, 14], with particular focus on tumour shape [8, 15]. The ef-35 fects of some of the currently available anti-tumour therapies have also 36 been analysed in the context of evolutionary dynamics [16, 17], with im-37 munotherapy [18, 19, 20, 21] and, recently, using agent-based modelling 38 in the context of virotherapies [22]. A number of reviews detailing the 30 evolution and the contribution of these and other models also exist in the 40 literature [23, 24, 25, 26]. 41

The focus of the present work is on metastatic secondary solid lesions, 42 with particular emphasis on the role of the immune system and mutations. 43 Scope of the this work is the study of the effects of different combination 44 45 therapies on secondary lesions in order to better understand the dynamics involved and the role of mutations on treatments' effectiveness. The rest of 46 the paper is organised as follows. In the "Model" section, a description of 47 the mathematical approach used to describe tumours, immune responses 48 and anti-cancer therapies is given. Findings obtained via computational 49 analysis are illustrated and analysed in the "Results" and "Discussion" 50 sections. Finally, the "Conclusions" section terminates the paper. 51

52 **2. Model**

53 Let us consider the biological setting under study as follows: a primary, clinically detected cancer is present in a patient and it is scheduled to be 54 treated with different therapeutic approaches, in an effort to improve the 55 patients' clinical outlook. A secondary lesion is also growing, undetected 56 and located away from the primary site, due to previous metastatic events 57 and migration of tumour cells belonging to the first lesion. We are inter-58 ested in understanding how the secondary lesion is affected by strategies 59 aimed at reducing the primary one. Our approach is based on an existing 60 mathematical model for tumour-immune interaction [27], which has been val-61 idated previously both from the point of view of biological appropriateness and 62 sensitivity to model parameters. The phenomena at hand are inherently complex 63 and there is a number of unknowns that still characterise these processes. Our

work is thus focussed on understanding the major trends and the typical out comes that can emerge in treating secondary lesions, providing some quantitative
 data that can be tested experimentally.

The dynamics between a heterogeneous, small, solid cancer lesion and 68 the immune system is formulated using an hybrid agent-based model 69 (ABM) coupled with a delay differential equation (DDE) system. An im-70 mune response to cancer cells that grow and mutate is simulated using a 71 population of cytotoxic T lymphocytes (CTLs), which mature in a tumour-72 draining lymph node. The overall approach rests on an existing frame-73 work, originally discussing tumour cells endowed with only a unique, sin-74 gle phenotype. The novelty of the present formulation lies in considering 75 more than one clone, with mutation processes strongly influencing and 76 shaping tumour growth dynamics. For a full analysis and description of 77 the model we refer the reader to Ref. [27], and only discuss the equations 78 briefly in the following. 79

The system describing immune activation is given by:

$$\begin{cases}
A'_{0}(t) = s_{A} - d_{0}A_{o}(t) - \alpha T(t)A_{0}(t), \\
A'_{1}(t) = V_{\text{ratio}}\alpha T(t)A_{0}(t) - d_{1}A_{1}(t), \\
C'_{0}(t) = r_{C}\left(1 - \frac{C_{0}(t)}{K}\right)C_{0}(t) - \mu A_{1}(t)C_{0}(t), \\
C'_{1}(t) = 2^{m}\mu A_{1}(t - \sigma)C_{0}(t - \sigma) - \mu A_{1}(t)C_{1}(t) + \\
+2\mu A_{1}(t - \rho)C_{1}(t - \rho) - \delta_{1}C_{1}(t) - fC_{1}(t), \\
C'_{2}(t) = \frac{fC_{1}(t)}{V_{\text{ratio}}} - \delta_{1}C_{2}(t),
\end{cases}$$
(1)

where *T* is the total cancer cell population and A_0 , A_1 , C_0 , C_1 , C_2 are the concentrations of antigen presenting cells (APC), mature APCs, memory CTLs, effector CTLs and CTLs, respectively. A sketch of the dynamics captured by the above equations is depicted in Fig.1.

The first two equations describe the transition from immature APCs circulating in the periphery to mature ones migrating to the lymph node as a response to tumour antigens.

The population of immature APCs is generated and dies at constant rates s_A and d_0 , with the maximum value of A_0 corresponding to the equilibrium level s_A/d_0 . When tumour antigens are presented, A_0 decreases proportionally to the antigenicity value α and mature APCs (A_1) begin entering the lymph node, with some dying at natural death rate d_1 .




Figure 1: **Immune system activation cycle** as described by the system of equation (1). The behaviour of the immune system is modeled as [27]

The presence of mature, tumour-antigen-bearing APCs in the lymph 92 node causes memory CTLs to activate and mature into effector CTLs, with 93 a certain delay. Consequently, the effector CTLs proliferate and migrate to 94 the tumour site where the anti-tumour immune response starts. This pro-95 cess is captured as follows. The third equation represents the stimulation 96 by the APCs of the memory CTLs (C_0), with a logistic growth rate inde-97 pendent of the external stimuli and a stimulation by mature APCs that 98 follows a mass action law. In the fourth equation, memory CTLs develop 90 a minimal division process, characterised by *m* times divisions, and evolve 100 in effector CTLs (C_1) with a time delay σ . Then, effector CTLs divide again 101 in a time ρ and flow away of the lymph node or naturally die with a rate 102 δ_1 . The last equation represents the concentration of CTLs (C₂) in the pe-103 riphery around the tumour and provides the concentration C_2 used by the 104 ABM component of the model to generate the boundary conditions for the 105 tumour-site domain. Table 1 shows parameter values used in this system 106 of equations and their meanings. Subsection 2.1 reports the parameter 107 estimation and the related sensitivity analysis, which have been mostly 108 performed in previous works [27]. 109

¹¹⁰ Cancer dynamics and immune cells response

The ABM controls tumour growth dynamics and the interaction be-111 tween tumour cells and CTLs at the tumour site, which follow specific 112 algorithmic rules. Our model does not consider healthy tissue around tu-113 mours and other structures such as the stroma or the cells part of a vas-114 cular network: it is assumed that tumour's surroundings are effectively 115 healthy cells being "pushed away" by the growing tumour. Note also that 116 no vascularisation is present due to the limited size of the secondary tu-117 mour lesion, which is considered to be small, solid and with no necrotic 118 core. Furthermore, other motility of metastatic processes from the sec-119 ondary lesion are neglected. The overall assumption is that the secondary 120 121 tumour is trying to colonize the site and is in its early stages of proliferation. All cells partaking the dynamics are represented as spheres of radius 122 *r* in 3D space, with no overlap. ABM is updated in discrete timesteps Δt . 123

CTL agents. The rules that govern CTLs cells via the ABM are three: 124 motion around the tumour, recruitment of other immune system cells and 125 killing of tumour cells. As mentioned, CTLs cells appear at a concentra-126 tion $C_2(t)$ at the border of the spherical domain representing the region 127 of interest where the tumour is growing. They then move into that re-128 gion performing Brownian motion in 3D space until they either collide 129 with a cell or leave the domain. At each time step, the position of the 130 cells are given by independent random variables with normal distribution 131 $\mathcal{N}(0,\sigma^2\Delta t)$, where the variance is such that $\sigma^2 = 2D$, with D being the 132 diffusion rate of the CTLs. When an immune cell comes into contact with 133 a cancer cells three possibilities exist: 134

• A CTL clone can be recruited with a probability $1 - e^{-\Delta t/C_{\text{recruit}}}$, with 135 C_{recruit} being the average recruitment time. Mathematically, CTL re-136 cruitment is modeled similarly to Mallet et al. [38] with cellular 137 automata, and it is biologically validated as in [39, 40]. When the 138 first CTL cell engages a cancer cell and starts recruiting another CTL 139 clone, a second cell appears at a position adjacent to the first cell. The 140 direction of the new clone is chosen randomly among all directions 141 available. 142

• A cancer cell is not recognised with a probability $1 - P_{i,recog} \cdot \Delta t$, where $P_{i,recog}$ is the probability of the i-th cancer phenotype (see below) to be recognised by the immune system. The parameter $P_{i,recog}$

has a value of one for cancer agents, expressing antigens completely 146 matching with the T-cell receptors and thus, that are always detected 147 by the immune system. A value of zero indicates that the antigens 148 of a phenotype are completely unrecognised. If the cancer cell is not 149 recognised, the CTL starts to move again choosing a new random di-150 rection and accelerating up to the maximum unit standard deviation 151 $\sigma_{\rm max}$. If $C_{\rm acc}$ is the time necessary to accelerate from the stationary 152 to the maximum diffusion rate, the CTL acceleration is computed as: 153 $\sigma(t) = \sigma_{\max} \cdot \min(t/C_{acc}, 1)$. This approach aims at approximating 154 CTL chemotaxis along a chemokine gradient [41, 42]. 155

• A cancer cell is recognised and killed with a probability $1 - e^{-\Delta t/C_{kill}}$, with C_{kill} being the average time for a CTL to eliminate a cancer cell. The killing process is obtained by removing the agent. After the agent is removed, the immune cell starts to move again as described above.

If CTLs die naturally, then they are removed from the system. An expla nation of the ABM-parameters is reported in Table 2 whereas parameter
 estimation and sensitivity analysis is discussed in Subsection 2.1.

Cancer agents. Tumour cells can proliferate, mutate or die, killed by 164 the immune system, and no migration is considered. This approximation 165 is motivated by the scope of the study, which is focused on the solid, grow-166 ing secondary lesion after the colonisation of a new tissue. In this early 167 stage of implantation most of the cells are assumed to be in a proliferation 168 state and migration can be neglected [50]. Cellular division occurs with a 169 probability $1 - e^{-\Delta t/T_{i,div}}$, i = 1, ..., 5, where $T_{i,div}$ is the average division 170 time of the i-th tumour phenotype. When a tumour cell divides, the posi-171 tion of a new cell is chosen randomly on the mother cell's perimeter, such 172 that the daughter cell is tangent. If no space is available in the chosen posi-173 174 tion, the division process fails and no new agent is created, mimicking the contact-inhibition mechanism occurring in the early stages of metastasis 175 implantation [51]. 176

¹⁷⁷ To analyse the effect of mutations on cancer development and immune ¹⁷⁸ response, we use five different cancer phenotypes that may emerge from ¹⁷⁹ the mutation of an *original* clone, identified by different values of charac-¹⁸⁰ teristic parameters $T_{\text{div},0} = T_0$ and $P_{\text{recog},0} = P_0 = 1$. Mutations can occur ¹⁸¹ during cell duplication, with a probability $P_{\text{mut}} \cdot \Delta t$ that aims to capture ¹⁸² the genetic instability of the system. Each mutated cell is then identified

by indices representing the level of expression of the two characteristic 183 quantities $T_{\rm div}$ and $P_{\rm recog}$. These values effectively classify the mutated 184 clones and the following mutated phenotypes. Modeling few phenotypes 185 of mutated cells is a simplification justified by several works showing that 186 only a limited number of phenotypes are predominant in a tumour, see 187 for example [8]. For the scope of our study, the five mutated clones are 188 prototypical of a wide range of similar mutations. In Table 3 cancer clonal 189 composition is considered. One of the assumptions is that only one class 190 of CTLs is modeled and it is not antigen specific. Although different types 191 of CTLs could take part in an immune response and act differently de-192 pending on the clone, our immune attacks are regulated only via $P_{recog,i}$. 193

¹⁹⁴ Using these different types of phenotypes, as we will see shortly, helps ¹⁹⁵ us to shed light on the role of mutations in determining the effectiveness of ¹⁹⁶ immune response and anti-cancer therapies. Different clonal compositions ¹⁹⁷ and reproductive and immunoediting advantages dramatically influence ¹⁹⁸ the outcomes of anti-cancer therapies.

¹⁹⁹ Modeling therapies: chemotherapy, immune boosting and radiotherapy

One of the typical features of secondary lesions is that they usually 200 show cells with mutated functional characteristics respect to the original 201 tumour, due to the genetic instability typical of metastatic masses they 202 originate from. We reiterate that there is no analysis of the fate of the 203 global cancer disease but only on such secondary lesions, which can show 204 different dimensions, compositions, structures and biological characteris-205 tics from the primary neoplasia. Chemotherapy, immune boosting and 206 radiotherapy are the strategies our modelling focuses on. 207

Chemotherapy. This treatment consists of cytotoxic drugs targeting a 208 specific cellular phase of the cell cycle to induce cell death. The procedure 209 acts against rapidly proliferating cells, independently from their nature 210 211 [52]. This means that healthy cells and immune system cells are usually damaged along with cancer cells, and this leads to well-known side effects 212 for the patients. In this work, only the primary killing effect against cancer 213 cells and no direct effects on the immune system is assumed. This simpli-214 fication is motivated by two main points. First, the average CTL lifespan 215 is 41 hours, whereas the tumour division rate is greater and the tumour 216 death rate due to the therapy is slower. CTL cells are rapidly affected by 217 the reduction of the tumour mass and no new CTL is recruited: the "old" 218 cells tend to naturally die. Second, if on one side chemotherapy affects the 219

immune cells, on the other specific T-cell response is reinforced [53], and
the investigation of these secondary effects is not in the scope of the future
present work.

During a cycle of chemotherapy of duration Ch_{time} , the i-th cancer 223 phenotype can go through cellular death with probability $1 - e^{-\Delta t/Ch_{kill,i}}$, 224 where the average time for the drugs to induce cellular death is $Ch_{\text{kill},i}$ and 225 depends from the proliferation potential of the phenotype. Ch_{time} takes 226 into account a single cycle of three injections every three days and rep-227 resents the global time duration of the chemotherapy's effects. The drug 228 remains two days above a certain percentage level such that the cytotoxic 229 effects on tumour cells can be considered constant. 230

Different values of Ch_{time} have been explored as reported in Table 4, 231 supposing that the same total dose is inoculated in continuous cycles of 232 low metronomic doses. The effect of different Ch_{time} with the same total 233 dose is a faster or slower decrease of the cancer population with similar 234 qualitative dynamics. In particular, for clone (0, 1) (refer to Table 3 for no-235 tation), i.e. the phenotype that grows slowly but is poorly immunogenic, 236 $Ch_{\text{kill},(0,1)} = Ch_{\text{time}}$, namely a (0, 1)-death is very rare. Clone (0 + 0.25*i*, 1 -237 0.25*i*), with i = 1, ..., 4, has $Ch_{kill,(0+0.25i,1-0.25i)} = Ch_{time} - i \cdot Ch_{eff} \cdot Ch_{time}$, 238 so that the tumour with higher proliferation rate has very high probability 239 to die due to the effect of the drug. 240

Immune boosting. We use this generic term to capture the number 241 of clinically available strategies that potentiate an immune response. For 242 example, a treatment that is increasingly used for cancer patients is the so-243 called adoptive cell transfer (ACT), where patients' own immune cells are 244 stimulated and modified to treat their tumour. There are several types of 245 ACTs that go under different acronyms depending on the boosting strat-246 egy employed, with the most used ones nowadays being TIL (lumour 247 infiltrating lymphocytes), TCR (Tumour cell receptors) T-cell and CAR 248 (Chimeric antigen receptors) T-cells treatments [54]. 249

²⁵⁰ We concentrate in particular on TIL therapy, where T-cells are extracted ²⁵¹ from the patient's tumour, grown *in vitro* to boost their numbers and in-²⁵² jected back into the patient to contrast cancer progression. This strategy ²⁵³ appears to be, for example, one of the most effective treatment against ²⁵⁴ metastatic melanoma [54]. In our approach, TIL is modeled as a contin-²⁵⁵ uous increase of the CTLs concentration in the cloud, depending on the ²⁵⁶ value of C_2 at the starting time for the therapy. The net increase is modeled by a number of *Bo_{eff}* cells for a short time *Bo_{time}*. For simplicity, in the
following we refer to this treatment as immune boosting or simply boost.
The parameters used to model boost and chemotherapy are explained and
collated in Table 4.

Radiotherapy. Radiotherapy (RT) uses ionising radiation to induce cell
 death in a localised area under treatment. This therapy has several posi tive and negative feedbacks on the immune system, modulating different
 compartments of the tumour microenvironment. In particular, tumour specific antigens and immune-stimulatory signals are released by the dy ing cancer cells.

Because of its contributing primarily to the original, metastatic neoplasia, the effect of RT is here modelled as an indirect effect on the secondary lesion and is accounted for as as a restoring factor in the ability of CTL cells to recognise and kill various cancer phenotypes.

271 2.1. Parameter estimation and sensitivity analysis

The biological significance of parameters and processes that underpin the present model has been discussed at length elsewhere [27, 55]. In some cases, such as, for example, parameters used for tumour division time or cell radius, well-established values in the literature have been used [43, 44, 45, 38]. In other cases, estimations from the available experimental and theoretical data have been carried out.

A sensitivity analysis has originally also been carried out for eight pa-278 rameters of the model: T_{div} , σ_{max} , C_{acc} , C_{recruit} , C_{kill} , K, μ , m and α . Other 279 parameters have not been considered because their role is known to be 280 marginal. For instance, the replenishment rate for memory CTLs is known 281 to be irrelevant, since only a very tiny fraction of memory CTLs (1%) is 282 known to be affected by the tumour. Similarly, the duration of CTL divi-283 sion (time delay parameter ρ in the DDE) is too small to impact the CTL 284 division program as a whole and does not influence final outcomes. Using 285 Spearman's rank-order correlations, tumour populations' values and ex-286 tinction times, Kim et al. have concluded [27] that tumour division times 287 $T_{\rm div}$, antigenicity α and the number of divisions of memory CTLs upon 288 activation *m* are the most sensitive parameters. 289

In this work, we use the same parameters proposed in the original paper, with the only difference of T_{div} , still chosen in the proposed interval but capturing a more aggressive tumour (i.e. $T_{\text{div}} = 1 - 39$ days). The effect on simulations is to shorten the proliferating phase, which occurs at
a larger growth rate and allows for a quicker immune response.

The new probability coefficients introduced here, i.e. P_{mut} and $P_{\text{recog, i}}$, have different effects. By using 5 different simulations with different initial random seeds and 10 different values of the parameters, we conclude that P_{mut} has no effect on the final outcomes of the system, but only accelerates or delays the identical dynamics shown by the model.

 $P_{\text{recog, i}}$ instead has a notable effect on the system. When $P_{\text{recog, i}} = 0$ for a given *i*-th clone, the immune system is unable to eradicate that particular phenotype and, if no external therapy is present, the tumour endlessly grows.

As far as the values for therapies' parameters are concerned, i.e. Ch_{time} , 304 $Ch_{\rm eff}$, $Bo_{\rm time}$, $Bo_{\rm eff}$, they are chosen so that the dynamics between tumour, 305 immune system and therapies display interesting behaviours and does not 306 result in an immediate negative or positive outcome. In particular, Ch_{eff} 307 and *Bo*_{time} have been varied in a number of different instantiations of the 308 model, with only the cases $Ch_{\rm eff} = 0.25$, $Bo_{\rm time} = 1000$ cells used in the 309 discussion of results. Variations of those parameters do not alter in a sig-310 nificant way the prototypical dynamics that we will discuss shortly. Note 311 that $Ch_{\rm eff} = 0.25$ has been chosen so that the cytotoxic drug targets fast 312 proliferating cells. 313

314 2.2. Morphological and complexity measures

Three indices that capture the shape and cellular compositions of the tumour mass are introduced and monitored in our computational experiments. Note that these indices can guide the evaluation of collective properties of the evolving tumours. They are useful to discriminate between different evolutions of the cancer masses and have also been validated in some in vitro experiments, as shown by other authors in previous works [56, 14].

Roughness. Although random proliferation of a group of cells leads to an almost smooth and spherical object, a tumoural mass with diverse clonal families under the action of the immune system can present itself as a rough aggregate. To account for this, a measure of roughness *M* is introduced, as the ratio between the surface *S* and the volume *V* of the aggregate [56]. The minimum ratio is represented by a sphere $S_s/V_s = (4\pi R_s^2)/(4/3\pi R_s^3) = 3/R_s$, where the value has been non-dimensionalised as follows: $M_{\min} = \sqrt{S_s}/\sqrt[3]{V_s} = \sqrt{4\pi}/\sqrt[3]{(4/3)\pi}$. The roughness index *M*,

expressed in terms of the minimal ratio for a sphere, is given by:

$$M = \frac{\sqrt{S}}{\sqrt[3]{V}} \cdot \frac{1}{M_{\min}} = \frac{\sqrt{4\pi S}}{\sqrt[3]{3(4\pi)^2 V}}.$$
 (2)

A compact, non-infiltrated, almost spherical tumour mass has an index *M* close to unity while a tumour with highly irregular borders, for instance a solid tumour with fingers and clusters of invasive cells or a mass highly infiltrated by the immune system, displays a higher value.

Radius of gyration. This value represents the radius of a sphere that contains the whole tumour aggregate and reads:

$$R_g = \sqrt{\frac{\sum_{i=1}^{N_c} (\mathbf{r}_i - \mathbf{r}_{cm})^2}{N_c}},$$
(3)

where N_c is the total number of cancer cells and \mathbf{r}_i is the distance of each clone from the center-of-mass of the tumour (\mathbf{r}_{cm}) that can vary during the tumour progression.

Shannon Index. This indicator is introduced to account for the presence of different phenotypes within a tumour, with regards to tumour heterogeneity and relative frequency of each clonal family (p_i). The Shannon index *H* is thus defined as:

$$H = -\frac{\sum_{i=1}^{s} p_i \ln(p_i)}{\ln(s)} \tag{4}$$

where p_i is the relative abundance of the phenotype *i* and *s* is the total number of different phenotypes (in our case s = 6). For simplicity, *H* is then normalised to the interval [0, 1], where zero indicates a homogeneous population with only one clonal family and unity represents a fully heterogeneous population where all phenotypes are equally present.

334 **3. Results**

The model outlined in the previous sections is the basis for *in silico* experiments, where a different number of therapies and their combinations

are tried out for significant values of the parameter set. Depending on 337 the initial conditions, the system exhibits three typical behaviours, namely 338 eradication, sustained (irregular) oscillations or exponential, uncontrolled 339 growth when an immune response to a growing tumour is present. We 340 consider parameter values where the effect of clinical therapies are rel-341 evant. Cases where the tumour grows too fast or too slow, making the 342 effects of therapies not noticeable, are excluded from our analysis. Sta-343 tionary behaviour has never been observed. Outcomes also depend on 344 the characteristics of cellular phenotypes present in the growing mass, 345 strongly influencing its speed of growth, its ability to counteract the ac-346 tion of T-cells with immunoediting and its morphological qualities, which 347 can hinder the ability of the immune system to effectively erode the cancer. 348 Considering the dynamics observed in a number of computational ex-349 periments performed at biologically meaningful parameter values, tumour 350 growth generally appears as exponential, with a consequent linear in-351 crease in the radius of gyration R_g with time, as previously observed [57]. 352 The main reason, as explained in Ref. [14], is that the growth is driven by those 353 *cells that reside at the periphery of the mass.* The nearly spherical shape of 354 the tumour when only a single clone is present changes significantly in 355 the presence of mutations. The greatest contribution to asymmetry occurs 356 when a new population with a faster proliferation rate than neighbouring 357 cells is generated. In that case, this new population forms an evolutionary 358 niche that can alter the sphericity of the tumour, until the new clones have 359 proliferated enough to surround the slower cells and recreate a spherical 360 appearance, as shown in Fig. 2. Note that, in our model, cells acquire 361 a new phenotype upon mutation in a purely stochastic way and there is 362 equal probability to mutate from the *original* phenotypes to all the others. 363 The heterogeneity of the mass increases with mutations until the faster 364 clones are not outnumbering the other phenotypes. If this occurs, then 365

366 the Shannon index H rapidly decreases with time in a way that it is inversely proportional to the growth of the more proliferating clones, i.e. 367 the faster they grow the faster H decreases. The action of the immune sys-368 tem usually tends to favor homogeneity over heterogeneity, rebalancing 360 the distribution of phenotypes as long as the immune response is active. 370 As T-cells erode the tumour, natural selection leads to an evolutionary bot-371 tleneck characterised by low H. It is interesting to note that the roughness 372 of the tumour tends to be in the interval $1 < M \leq 1.5$, with signs of super-373 ficial infiltration by the immune system. The limited life span of the CTLs 374




Figure 2: **Tumour growth dynamics** Panel (A) R_g as function of time, slow initial trend followed by a fast linear growth. Panel (B) *H* as function of time, increases with mutations and decreases when the fittest clonal population outnumbers the others. Panel (C) *M* as function of time. The roughness index increases with mutations, is higher when a new population with fast proliferation arises and reaches an almost stationary level when *H* is near zero. Panel (D), (E), (F) 3D-views of the tumour, respectively, just after the birth of the fittest clone (t=30 days), when the fittest population starts to invade (t=36 days), when the tumour returns to growing almost spherically with low grade of heterogeneity (t=50 days).

used in our model tends to promote attacks that occur on the periphery
and rarely result in deep infiltration, which, as we will show shortly, is
instead present when therapies are activated.

³⁷⁸ *The effect of therapies on tumours*

In the following, all the parameters have been set as in Ref. [27] and 379 are reported in Tables 1 and 2. The tumour mutation rate has been chosen 380 following the principle that positive mutations, i.e. mutations that lead to 381 an evolutionary benefit to the cells over therapies and immune response, 382 are rare. As it is expected, the dominant phenotype population usually 383 appears after a clonal expansion of few mutations. The range of variation 384 of the proliferating, aggressive tumour has been set to ensure a biologi-385 cal meaning and a rate of growth that allows the cancer mass to escape 386 the control of the immune system in a limited range of time. The main 387 reason for this choice is that we are interested in modeling the impact of 388 different therapies on cancers that will not be eradicated in the absence 389 of anti-tumour therapies and that, at the same time, do not show growth 390 rates that are unrealistic. Thanks to the probabilistic structure of the sys-391 tem, simulations can generate different outcomes also when parameters 392 are kept fixed for the particular cancer studied. Among the different ex-393 periments, three paradigmatic dynamics emerge, which bear particular 394 relevance and help understanding the typical scenarios that our model 395 predicts. They are the result of stochastic variations on the evolution of 396 initially identical tumours. These cases respectively correspond to a tu-397 mour mass with an initial slow growth and high heterogeneity (case A), 398 and two fast growing tumours with either initial low (case B) or high (case 399 C) heterogeneity. 400

401 *First single-therapy strategy: chemotherapy*

Our first choice is to simulate a cytotoxic chemotherapy that acts with more efficiency against the cancer cells that have the largest growth rate, starting at day 60 after the first tumour cell colonizes the site and for a total duration of 10 days. The probability of a cell to be killed by chemotherapy, with a total dose of drug fixed, is set independently from the time duration of the protocol in an effort to maximize the efficiency of the therapy.

Fig. 3 shows the evolution of the tumour cell population as a function of time, according to different phenotypic compositions. In the following, time is evaluated starting from the instant at which the original clone starts to colonize the new organ. This time does not refer to the primary tumour or the history
of his evolution.. In panel (A), the effect of chemotherapy on tumour case A,
which is representative of those cancers with lower rates of proliferation
but higher propensities to mutate.

A too early start of the treatment results in a completely ineffective 415 strategy, with a negative outcome. This is because chemotherapy reduces 416 the more proliferating cells (in pink) at day 60 when those cells are still 417 scarce and the tumour is too small to benefit from the action of the cyto-418 toxic drug. Once the treatment is over, the remaining cells restart to mu-419 tate and proliferate, with an exponential growth that the immune system 420 alone cannot contain. As shown in the inset of panel (A), the number of 421 cells belonging to the original phenotype (in black) remain almost constant 422 throughout the procedure and do not change significantly for the duration 423 of the experiment. 424

Panel (B) of Fig. 3 instead shows a complete eradication of case B, 425 426 where tumour cells have initially a low heterogeneity but are reproducing fast. The effect of the therapy is in this case to eliminate every cell 427 belonging to the dominating, fast-reproducing phenotype before it is over, 428 i.e. approximately around day 7 of its 10 days duration. Also, all cells of 429 the original phenotype are eradicated by the end of the treatment, with the 430 tumour completely cleared out by the effect of the cytotoxic drug and the 431 immune response. 432

An initially fast reproducing tumour with high heterogeneity can instead lead to uncontrollable rebounds, with an overall negative outcome for the patient. In panel (C), the action of the chemotherapy is not sufficient to eliminate every single cell belonging to the mutated phenotype. According to our choice of parameters, it is enough that one original cancer cell or one of the more proliferating clone survives after the chemotherapy that a fast, uncontrollable rebound can be expected.

Interestingly, these last two cases (i.e. B and C) do not show different 440 evolutions of the radius of gyration R_g (not shown in the Figure) during the 441 action of chemotherapy, since the treatment acts homogeneously on the 442 cancer mass as a whole. This is associated directly to the limited dimen-443 sion of the tumour, leading to the drug acting on the aggregate with a high 444 strength from all spatial directions. Roughness M instead show significant 445 changes from case A and cases B and C. Tumour case A remains spherical 446 and compact during the experiment, essentially because the treatment has 447

a very limited effect on the mass due to its premature start. Tumour case B 448 and C, instead, reach high level of roughness during the treatment, show-449 ing, for the cases reported in the Figure 3, a maximal M of 3.77 and 3.45, 450 respectively at day 64 and 65 for cases B and C. This clearly indicates that 451 the tumour loses density and becomes morphologically inhomogeneous 452 at around half of the treatment duration and is infiltrated to a relevant 453 degree by the T-cells taking part in the immune response. The overall con-454 sideration from these results is that the correct timing of treatment, *here* 455 intended as the ideal treatment starting time and therapy duration to achieve op-456 *timal patients benefit*, is a major variable for the outcome of the treatment 457 and it is also strongly affected by phenotypical compositions. 458

459 Second single-therapy strategy: immune boosting

The overall effect of immune boosting is to increase the number of CTL 460 cells circulating around the tumour site, which we simulate as an injection 461 of cells starting at day 50 and occurring for a duration of 3 days. Erosion of 462 cancer cells by the immune system proceeds from the periphery towards 463 the center of the tumour mass, and is usually characterised by a linear de-464 crease of R_g during the first few days. Another typical characteristics of 465 the dynamics that follows boosting is a clonal expansion of the CTL pop-466 ulation shortly after treatment. For the prototypical three cases A, B and 467 C introduced above, all of our computational experiments indicate that 468 boosting alone is not able to eradicate cancer: after an initial decrease in 469 the tumour mass, two types of evolutions have been observed, both re-470 sulting in negative outcomes. Of particular relevance is case C, which, 471 although not treatable by chemotherapy alone, shows a somewhat unex-472 473 pected and complicated morphology when subject to immune boosting. In fact, after an initial clonal selection of the less immunogenic phenotype, 474 case C displays a clear deviation from sphericity in the mass, with a non-475 local spread of the tumour population in islands of different sizes, as re-476 ported in Fig. 4. After a decreasing phase due to an immune response that 477 does not result in a complete eradication, the tumour population is even-478 tually subject to a faster, uncontrollable increase driven by disconnected, 479 smaller masses. Overall, a selection of 5 parameter sets and 10 trials for 480 different seeds give qualitatively similar results. 481

Panel (A) in Fig. 4, shows the number of cells for each phenotype as a function of time: an initially exponential growth is firstly slowed down then halted by immunotherapy, with a maximum cell population occur-




Figure 3: **Chemotherapy effect** Number of cancer cells and phenotypical composition as functions of time. Chemotherapy starts at day 60 and lasts for 10 days. Panel (A) shows an initial phenotype (in black) with slow reproductive rate (case A), eventually overtaken by a new phenotype that reproduces very fast (in pink). The inset shows cellular distribution during the last part of the treatment. Panel (B) shows an initially fast reproducing tumour with low heterogeneity (case B), with an inset of the last two days before complete eradication. Panel (C) depicts an initially fast reproducing tumour with high heterogeneity (case C), with the inset focusing on the dynamics at the end of the treatment and in the first days of the rebound phase.




Figure 4: **Immunotherapy effect.** Results for the prototypical case C, a fast growing cancer with high phenotypical heterogeneity. Boost immunotherapy starts at day 50 and lasts a total of 3 days. Panel (A): time series of each cell population, panel (B): snapshot of the tumour mass at time t = 170 days.

ring about 20 days after the beginning of the treatment. Around day 100, the evolution of the cell population changes. Frequent, local maxima in both tumour and T-cell curves represent the failed attempts made by the immune system to completely erode the tumour due to the increasing sparseness of the cancer. This behaviour seems to occur for a protracted period of time of about 60 days.

As the cells in the island's sizes begin to proliferate faster than the rate of killing of the T-cells, a rebound phase with a higher speed of growth than the *original* unbroken mass appears at day 180. Panel (B) provides an image of the scattered status of the tumour immediately before its exponential rebound. Let us remark that the model does not allow for migration of cancer cells and this picture is the result of the infiltration of T-cells coming from boosting and immune response.

As expected, morphology immediately before the rebound phase is characterised by a high value of roughness, with $max(M_{CaseC}) = 2.16$ at day 162. Also, there is almost a twofold increase in R_g compared to the value for identical number of cells in the first growth phase. For example, for 10^4 cells, we have $R_{g_{CaseC}} = 125$ at day 47 and $R_{g_{CaseC}} = 240$ at day 160.

⁵⁰³ *First example of synergistic therapy: chemotherapy and boosting*

Cancer heterogeneity has been invoked to explain one of the major as-504 pects of cancer development, namely acquired drug resistance, by which 505 phases of remission are often followed by a rapid growth of tumour cells [3] 506 One of the ways to overcome resistance is, for instance, to find more "evo-507 lutionarily enlightened" strategies that places malignant cells in an "evo-508 lutionary double bind" [17]. In cancer, a double blind could be obtained 509 using the immune system as natural biological predator [58]. Clinical 510 evidence shows that immunotherapy or oncolytic viruses alone are not 511 effective, despite the possible theoretical advantages. Therefore, cancer 512 treatment is adopting a multistep approach that combines biological and 513 514 chemical/radioactive therapies using cytotoxic effects on one side and subsequent adaptation on the other side to limit tumour adaptive resis-515 tance [59, 60]. 516

Guided by the poor outcomes displayed by immune boosting alone in 517 the prototypical cases, we now consider the combination of chemotherapy 518 and immune boosting, with the aim of discussing the major factors that 519 maximize positive outcomes. The prototypical cases have been subjected 520 to a protocol of an immune boosting injection at day 50 lasting three days, 521 followed by a chemotherapy session at day 60. Results are displayed in 522 Fig 5, with the insets displaying phenotypical composition over time. For 523 cases A and B, the complete temporal range is shown, whereas for C the 524 last 20 days are reported. Timing for these therapies has been chosen arbi-525 trarily. For cases B and C the second lesion grows up to numbers of tumour cells 526 that are close to the detectability threshold. 527

The effects of this synergistic therapy in cases A and C are similar: 528 chemotherapy preferentially kills those cells that are fast to reproduce, 529 leaving the slowest reproducing phenotype unaffected. As a result, re-530 bounds occur once therapies end, with case A showing a negative outcome 531 within the simulated time window and case C displaying a still moderate 532 but uncontrollable growth at the end of the simulation. In other words, the 533 effect of chemotherapy is to create an evolutionary bottleneck that selects 534 the poorly immunogenic clones. In particular, case C (see the inset of Panel 535 (C)) shows a surviving tumour composed by only two clones: the clone (0,1) and 536 the clone (0.25, 0.75): these are the two families that are the slowest in proliferat-537 ing and have the lowest immunogenicity. These clones have a strong immu-538 noediting ability and remain unnoticed by the immune system, resulting 539




Figure 5: **First kind of synergistic therapy: chemotherapy and immune boosting.** Plots represent the time evolution of cellular populations, with insets showing phenotypical composition of the tumours with time. Immune boosting starts at day 50 and lasts 3 days, whereas chemotherapy starts at day 60 and has a duration of 10 days. Panel (A), (B) and (C) respectively show cases A (slowly growing tumour), B (quickly growing tumour, low heterogeneity) and C (quickly growing tumour, high heterogeneity). *Note that different scales have been used to allow for greater details of the dynamics. The inset in Panel (C) represents a close-up of the time range* 90 – 110 *days. The unit on the* y– *axes of every plot in the Figure is cells' numbers.*

in unending growth: because of their ability to be elusive to both the immune 540 response and chemtherapy, outcome C appears the worst of all. Note that, for 541 this reason, this phase is of a different nature than those previously re-542 ported for individual therapies (i.e. Figs. 3 and 4). Also, because of the 543 low heterogeneity of case B, this combined therapy is instead successful in 544 fully eradicating the tumour, which is eliminated during the administra-545 tion of the cytotoxic drug. On the other hand, case A, differently from the 546 results obtained for chemotherapy alone, displays a selection of the poorly 547 differentiated immunogenic clones. 548

From the morphological perspective, masses emerging from this syn-540 ergistic intervention appear to be low in roughness when the reproduc-550 tive rate is slow, with $max(M_{CaseA}) = 1.62$ at t = 81 days. If the rate 551 is instead fast, the level of heterogeneity usually determines the level of 552 roughness, with low heterogeneity contributing high roughness during 553 the chemotherapy phase, i.e. $max(M_{CaseB}) = 3.05$ at t = 64 days and 554 $max(M_{CaseC}) = 2.64$ at t = 63 days. Contrary to case B, case C shows a 555 Shannon index of H > 0.5 for most of the simulation, which results in an 556 unsuccessful eradication. 557

Other time protocols and order of administration between boosting and chemotherapy are possible, and have been tested to some degree (results not shown here). Although a study of optimisation of protocols is not within the scope of the present work, the overall insight from the simulations is that heterogeneity always plays an important role in the outcomes. For this combination therapy, high values of *H* are consistently associated with negative prognosis [61].

Second example of synergistic therapy: radiotherapy, boosting and "abscopal"
 effect

A second example of synergistic therapies that is currently used in clin-567 568 ical practice is the combination of an initial cycle of radiotherapy with an immune boosting protocol. Besides a better understanding of the param-569 eters that can trigger a positive outcome, our interest in testing such a 570 combination resides in the occurrence of a somewhat rare and poorly un-571 derstood event, which is named "abscopal" effect. There are a number 572 of clinical cases discussed in the medical literature where a reduction of 573 a secondary tumour or an existing metastasis outside the primary, radi-574 ated lesion has been observed [62, 63, 64, 65, 66, 67]. Differently from 575 chemotherapy, radiotherapy has a localised action on the region irradiated 576

and this makes the phenomenon, to some extent, counterintuitive. Sometimes, the effect appears to affect a secondary lesion very distant from the
region treated.

The complications inherent to the stimulation of such an event are due to the immune action apparently being as crucial as radiotherapy in triggering such a response.

The model allows us to test some hypotheses on the nature and causes 583 of the effect of protocols introduced by Demaria et al. in Ref. [68], who 584 have reported some interesting and positive outcomes. In particular, they 585 have treated mice with a syngeneic mammary carcinoma in both flanks 586 with immunotherapy and only one of the two tumours with radiother-587 apy. They use the non-irradiated lesion to monitor the insurgence of the 588 abscopal effect. Biologically, a tumour-specific T-cells activation occurs af-589 ter inflammatory signals are introduced in the system as a consequence 590 of the therapy. Dying cancer cells release tumour-specific antigens and 591 immune-stimulatory signals that seem to induce an increased recognition 592 593 of cancer cells with the same phenotypical characteristics in other areas of the body. Further, radiation modulates different compartments of the 594 tumour microenvironment, resulting in exclusion-inhibition of effector T-595 cell and induction of de novo anti-tumour immune responses [69]. The 596 protocol that we simulate is a radiotherapy (RT) on the primary tumour 597 (not simulated or showed here) at day 1, followed by an immune boosting 598 that lasts 10 days. As anticipated, RT is considered a restoring factor in 599 the ability of CTL cells to recognise and kill all cancer phenotypes, with no 600 exceptions. 601

The secondary lesion is composed of 5×10^4 heterogeneous cells (the 602 same number of cells injected in mice in the experiment by Demaria et al.), 603 generated randomly with each clonal family representing at least 10% of 604 the total population. We compare the action of two single therapies (RT 605 606 and immune boosting), with a combination of the two and a control case where the second lesion remains untreated. Results are presented in Fig 6: 607 each panel represents the typical outcome from a single simulation. For each case, 608 *i.e.* control (no treatment), combination, immunotherapy, and radiotherapy, we 600 have performed three different simulation runs, with different initial conditions. 610 The outcome of each simulation for any configuration consistently gives compa-611 rable results. Variation due to stochasticity are minimal and do not affect the 612 outcomes. 613

⁶¹⁴ Firstly, no treatment or RT alone result in similar negative outcomes for

the secondary mass, not directly treated by RT, both from the perspective 615 of surviving cancer cells (panel (A)) and the response of the CTLs of the 616 immune system (panel (B)). An initial RT with no follow-up has the only 617 effect of delaying an exponential rebound, not dissimilar to the behaviour 618 of an untreated mass. Boosting alone does not impact the mass as much 619 as when we combine boosting and R1, with the former giving rise to a 620 tumour that after 30 days has less than half the mass than in the case of 621 chemotherapy alone. Stimulated by the release of the antigens of the dead 622 tumour cells of the primary lesion, both therapies show a maximum in the 623 number of active CTLs, which occurs around day 7 and is then followed 624 by a characteristic drop around day 10. Qualitatively the results of the 625 model reproduce the experimental data in Ref. [69], with indications of a 626 start of a remission for the secondary tumour. 627

Different strategies on the secondary mass also lead to different clonal 628 compositions, which have an effect on the final outcome. One of the keys 629 for the success of the strategy is to have no phenotype prevailing over 630 the others, as shown in panel (C) for the combination of RT and immune 631 boosting and, to a lesser extent, in panel (D) for immune boosting alone. 632 Note that the width of the coloured regions in panels (C)-(F) indicates the number 633 of cells that belong to a specific clone population: the larger the width, the larger 634 *the population.* For example, combination therapy provides a very high 635 Shannon index, H > 0.99, throughout the whole duration of the experi-636 ment. RT and no treatment show instead reduced indices, with values at 637 day 30 of 0.43 and 0.55 respectively. Interestingly, the RT case appears to be 638 less heterogeneous than the control case. Overall, it is important to stress 639 that, for the case of the secondary lesion, high heterogeneity is not per se 640 associated to a worse prognosis. The reason is that a successful action on 641 the secondary mass reduces the fitness advantage of the phenotypes and 642 makes the immune system able to recognise each clones equally. *Note that* 643 644 Panel (E) refers to the radiotherapy case made on primary tumour, showing the evolution of the secondary mass and the fact that the immunogenic effects induced 645 by the treatment are not sufficient to contrast cancer growth. Panel (F) represents 646 the control case, where no treatments are administered and the tumour is growing 647 unchallenged as an aggressive breast cancer. 648

We find that the relation between the phenotypical composition of the primary and secondary lesions plays a very important role in the dynamics of the so-called abscopal effect. The previous examples refer to a secondary lesion that is antigenically related to the first tumour, but this is not




Figure 6: Effects of anti-cancer treatments on a secondary tumour. Panel (A and B): Cellular populations of a secondary tumour as functions of time, with cancer populations depicted by a continuous line (panel (A)) and CTLs population by a dashed line (panel (B)). Each color corresponds to a different treatment. *These curves represent a typical simulation run. Variability due to stochasticity is minimal.* Other panels show phenotypical composition of the secondary tumour for the *curves shown in Panels (A)-(B)) and for the* following strategies applied the primary tumour: combination therapy (panel (C)), immune boosting (panel (D)), radiotherapy (panel (E)), no treatment (panel (F)). Each color indicates a different cancer clone family. *Legends show labels for such families, whose properties are described in detail in Table 3.*

always the case in practice. Results vary considerably if the phenotypical
 compositions differ and this is important to stress.

For example, if the secondary tumour is characterised by clones that 655 are not antigenically related to the first lesion, the final outcome of combi-656 nation therapy cannot be as positive as in the previously discussed cases. 657 Given that radiotherapy affects phenotypes that are distributed in differ-658 ent ways in the first and second tumours, the immune system is not capa-659 ble of recognising specific tumour cells in the same successful way as in 660 the previous examples. As a result, the therapy shows a worse outcome, 661 as can be seen in Fig. 7(a). Furthermore, if the second tumour mass is in-662 stead implanted in an immune suppressed host (mathematically obtained 663 by setting $\alpha = 10^{-15}$), where the level of CTLs circulating around the tu-664 mour is lower than ordinary levels, the outcome is negative. As reported 665 in Fig. 7(b), a reduced fitness of the immune system causes one pheno-666 type to prevail over the others and proliferate quickly out of control. It is 667 reasonable to suppose that, if more cycles of therapies are repeated, the 668 effectiveness of treatments is likely to be also reduced. 669 670

671 Mutation rates and eradication of secondary tumours

A complete eradication of a secondary tumour as an indirect result 672 of an anti-cancer therapy on a primary lesion is a relatively rare occur-673 rence. Also, it appears to be associated mainly with certain types of cancer, 674 namely melanoma or breast cancer. This might be linked to the fact that 675 generic metastatic events are characterised by a high genetic instability, of-676 ten making secondary lesions phenotypically unrelated to the first tumour. 677 From this point of view, a possible speculation could be that the so-called 678 abscopal effect is not a rare event per se, but it is an effect limited to sec-679 ondary tumours that have a phenotypical clone composition that is not 680 too dissimilar from the originally treated lesion, and thus the effect only 681 seldom changes the prognosis for secondary lesions. Indeed, extensive 682 genetic and phenotypic variation are known to strongly influence thera-683 peutic outcomes [70]. 684

To investigate how the rate of mutation of cancer cells affects outcomes on secondary lesions, we generate a tumour of 5×10^4 cells with a full mutation capability and apply a combination therapy (RT and immune boosting) as per the previously introduced protocols. In other words, the complete secondary lesion before the start of treatments is composed by




Figure 7: **Immune mediation on a secondary lesion.** Tumour size and composition as functions of time for three different secondary tumours, subjected to different antitumour strategies on the primary tumour. Panel (A) shows results for a secondary tumour antigenically unrelated to the primary and panel (B) shows the outcome for a secondary tumour that is antigenically related to the primary tumour but implanted in an immune-suppressed host. *Legends show labels for the tumour subpopulations emerging from the original population, via secondary mutations caused by the therapies. Properties of each clone family are described in detail in Table 3.*

the *original* clone. Typical results are reported in Fig 8(a) and show that 690 outcomes do not linearly depend on the rate of mutation. Interestingly, 691 tumour reductions at day 30 are larger when the mutation rate is lower, 692 but become negligible when the rate of mutation is approximately larger 693 than $P_{\text{mut}} = 0.6$, with no relevant change in the overall outcome for higher 694 rates (see purple, yellow and cyan lines). Also, for rates lower than $P_{\rm mut} =$ 695 0.1 (see blue and black lines), different dynamics of eradication can be 696 present, with tumours having different cell counts after the treatment is 697 administered, although the final result at day 30 appears almost identical. 698 Heterogeneity tends to increase with the mutation rate, but its max-690 imum value during therapy is not directly proportional to how fast the 700 system can mutate. After a given rate of mutation, which is approximately 701 $P_{\rm mut} \approx 0.5 - 0.6$, mutations do not increase the heterogeneity of the mass. 702 This is because the fittest clone usually becomes dominant, its cells out-703 number the other phenotypes and heterogeneity reduces. Fig. 8(b) shows 704 that the maximum values of *H* are a concave function of mutation proba-705 bility. Also, the overall distribution of phenotypes in the secondary mass 706 is, as discussed previously for the case of a single cancer, strongly affected 707 by the morphology. 708

Different rates induce different roughness as shown in Fig. 8(c), where 709 the maximum value of M reached by the tumour mass is plotted as a func-710 tion of mutation rate. This value increases for small rates and reaches a 711 maximum for a rate $P_{\text{mut}} = 0.2$, followed by a sharp decrease. For rates 712 larger than $P_{\text{mut}} = 0.5$, the value does not change significantly. Tumour 713 morphology of the secondary lesion influences how the immune system 714 progresses in its attack. In our simulations, we observe different dynamics 715 of attack carried out by the immune system, with the tumour being eroded 716 in different ways and often not in a homogeneous fashion. Nonetheless, 717 a rougher tumour always appears more vulnerable to immune system at-718 tacks because of the degree of infiltration by CTLs it allows. Even in "ab-719 scopal" positive outcomes, infiltration plays a major role in the dynamics 720 of erosion and high M correlates with better results. At the highest mu-721 tation rates, roughness is low because the immune system is not able to 722 recognise phenotypes that are different from those of the primary mass 723 and kill them. This results in a fast, unbounded growth of one or two 724 phenotypes that increase the sphericity of the mass and quickly lower the 725 roughness value approximately to unity, which corresponds to a spherical 726 object. This is reflected in the plateau observed in Fig. 8 for $P_{\text{mut}} > 0.5$. 727




Figure 8: **Dependence of eradication of the secondary lesion from its mutation rate.** Results for secondary lesions with different mutation rates, when a combination therapy is administered to the first lesion. Panel (A): Total cancer population as function of time for different P_{mut} . At day 0, the secondary tumour mass is phenotypically identical to the primary lesion. Panel (B) and (C): Maximum values of the Shannon index *H* and of the roughness *M* as functions of the mutation rate. *Points in the Figure represent results from single simulations. Maxima in panels (B) and (C) have been taken over time for each rate of mutation for the clones.*

728 4. Discussion

Cancer and immune cells are complex systems with different charac-729 teristics that also depend on internal and external evolutionary pressures. 730 In the last decades, improvements on the general knowledge of these pro-731 cesses have stimulated new therapeutic strategies which take into account 732 to patients' particularities to some degree. The detailed model of immune 733 interaction described here focuses on the salient traits of the dynamics and 734 is able to reproduce the major features of a number of therapeutic inter-735 ventions. 736

An analysis of the effect of different drugs on three prototypical sec-737 ondary masses arising from a metastatic breast cancer (not modeled) has 738 been proposed, showing a faithful representation of some of the main 739 mechanisms of tumour-immune interactions present in literature [20, 9]. 740 In particular, we note a significant dependence of the outcomes on the 741 heterogeneity of the tumour, with higher heterogeneity generally corre-742 lated with negative outcomes confirming biological evidence suggested in 743 Ref. [70]. Indeed, therapies targeting heterogeneous cancer micro envi-744 ronments often show large rebounds of more resistant tumour cells, that 745 are able to counteract the action of drugs or boosting in a consistent way. 746 In particular, one original result from our modeling is that chemotherapy 747 appears more efficient in a less phenotypically differentiated secondary le-748 sion independently of the rate of growth or the dimension of the mass. For 749 the reproductive rates considered in this study, immune boosting alone is 750 not sufficient to produce full eradication, but rather can trigger the spread 751 of the more aggressive cells in the body by making the existing mass more 752 sparse. A well-timed intervention with a combination of boosting and 753 chemotherapy seems to be the safest of the protocols, allowing for a rele-754 vant reduction of the mass and preventing the unbounded growth of the 755 most proliferating cells. Nevertheless, timing of intervention on the sec-756 ondary lesion can be critical. 757

One further result of this work is to uncover the importance of tumour morphology in evolution and fate of secondary lesions. The shape of secondary masses conveys important information that could be an indicator of successful eradication. For instance, during or immediately after administration of chemotherapy, our modeling shows that a high infiltrated tumour is associated with the best outcome. At the same time, a harsh environment or a high selective pressure tend to generate a tumour

that has a greater roughness and the tendency to spread, as previously 765 noted [8]. This often occurs and persists for many days after adminis-766 tration of chemotherapy. In particular, findings for case A suggest that 767 clonal composition of surviving cells that originated from the beginning 768 tumour colony, and are later influenced by the selected therapies, strongly 769 affect the final outcomes of the metastasis. Similar dynamics is reported 770 to be present in some types of tumours that are known to be particularly 771 resistant to therapies [71]. 772

Here we consider one cycle of treatment, but some extra *care* should 773 be taken when multiple cycles are considered, since the immune system 774 could be further weakened and respond less efficiently. On the other hand, 775 there is evidence in the medical literature that a combination of radiother-776 apy and immunotherapy can provide a positive effect not only in the area 777 affected by the radiation but also in other areas of the body. This seems 778 to be due to the release of autologous neoantigens to the immune system 779 [69], with the overall result of what it appears to be an individualised tu-780 781 mour vaccine. Our model captures the effects of this cascading action on a secondary metastatic mass and confirms that the immune system can 782 act as a mediator for secondary attacks. In particular, there is evidence in 783 our findings that immune-suppressed hosts or secondary lesions antigeni-784 cally unrelated to the treatment area do not show any abscopal effect, as 785 experimentally noted. 786

There is a growing discussion in the community about the causes of 787 this rare, positive occurrence on secondary masses. Currently, it seems 788 that this is the result of a fragile balance between positive and negative 789 signals activated with the radiation, dependent on the pre-existing envi-790 ronment and the immunogenicity of the tumour [69]. These biological 791 elements, alongside a critical dependence on the dose and the interval be-792 tween radiation fractions, contribute to the low occurrence of this effect. 793 Furthermore and interestingly, a dependence of the effect on the mutation 794 rate of the cancer clones in the secondary site is apparent, suggesting that 795 the role of genetic instability at that site should be investigated more. 796

Overall, our findings emphasises that the morphology of the secondary lesions before, during and after the treatment, bears some indications of the rate of success for the treatment. For the lesions under the detectability threshold, this work suggests that heterogeneity and roughness are both important quantities. Negative prognosis is linked to the selection of a poorly immunogenic clone and has been shown to lead to a large, un-

bounded regrowth of the tumour. It is thus vital to design a protocol that 803 can minimize the immunoediting ability of cells surviving from therapies 804 or improve the immune system ability to recognise and attacks such clones 805 especially when we cannot detect individual, isolated lesions but only to-806 tal tumour burden. In regards to the latter, the activation of an "abscopal-807 like" response seems to be a strategy in re-calibrating the immune reaction 808 to such cells. Results are still in their infancy and it is unknown whether 809 such a response can be elicited and how. One of the ideas we suggest is to 810 carefully consider the best tumour target to be irradiated: when possible, 811 it could be advantageous to target a secondary metastasis antigenically re-812 lated to the more common lesions in the body, with a low grade of hypoxia 813 and with a good grade of immunogenicity. 814

815 **5.** Conclusions

Cellular mutation constitutes one of the causes of negative outcomes 816 in therapeutic strategies against cancer. Morphology, growth rates and 817 the clonal composition of a tumour mass can, to some extent, be used as 818 predictors of tumour resistance to a range of anti-cancer therapies and be 819 analysed to combine treatments to maximize their impacts. In most of 820 the commonly used protocols, the action of the immune system is cru-821 cial. Modern therapies elicit and enhance patient's immune response, also 822 because of its ability to adapt to, change and modify the tumour microen-823 vironment. 824

The mathematical model we have presented tries to capture the com-825 plexity of tumour-immune dynamics and discuss how therapies with dif-826 827 ferent scopes, doses and protocols can influence prognosis for small, solid, secondary tumoural lesions. Even if these lesions can be small and not yet de-828 tectable, their role can be catastrophic for the patient if they are untreated or, as 829 in some cases we have shown, the effect of therapies on the primary tumour can 830 lead to the selection of more aggressive and resilient clones in the secondary le-831 sions. Ideally, individual, evidence-based modelling might provide a fast, 832 reliable and patient-centred way to test and find optimum control of pro-833 tocols in vivo. 834

Our findings suggest that the success of synergistic therapies is strongly influenced by the phenotypical composition of all the lesions, alongside their mutation rates and immunogenic properties. Effective strategies that can "normalise" the microenvironment [72] and will try to limit tumour clonal mutation could be trialled to improve prognosis. Therapies that target slowly proliferating and undifferentiated cells can also become viable
in the future.

842 6. Acknowledgements

EP, PSK and FF gratefully acknowledge support for this work through
 the Australian Research Council Discovery Project DP180101512, Dynam ical systems theory and mathematical modelling of viral infections.

7. Code and Data availability

The code used and the produced data for the simulations discussed in this work are available upon request.

References

- [1] D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646–674.
- [2] D. P. Tabassum, K. Polyak, Tumorigenesis: it takes a village, Nature Reviews Cancer 15 (2015) 473–483.
- [3] M. Gerlinger, C. Swanton, How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine, British Journal of Cancer 103 (2010) 1139–1143.
- [4] A. Sottoriva, H. Kang, Z. Ma, T. A. Graham, M. P. Salomon, J. Zhao, P. Marjoram, K. Siegmund, M. F. Press, D. Shibata, et al., A big bang model of human colorectal tumor growth, Nature Genetics 47 (2015) 209.
- [5] A. Rübben, A. Araujo, Cancer heterogeneity: converting a limitation into a source of biologic information, Journal of Translational Medicine 15 (2017) 190.
- [6] J. M. Pacheco, F. C. Santos, D. Dingli, The ecology of cancer from an evolutionary game theory perspective, Interface Focus 4 (2014) 20140019.

- [7] T. Hillen, M. A. Lewis, Mathematical ecology of cancer, in: Managing Complexity, Reducing Perplexity, Springer, 2014, pp. 1–13.
- [8] A. R. Anderson, A. M. Weaver, P. T. Cummings, V. Quaranta, Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment, Cell 127 (2006) 905–915.
- [9] L. G. De Pillis, W. Gu, A. E. Radunskaya, Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations, Journal of Theoretical Biology 238 (2006) 841–862.
- [10] S. Wilson, D. Levy, A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy, Bulletin of Mathematical Biology 74 (2012) 1485–1500.
- [11] A. D. Asatryan, N. L. Komarova, Evolution of genetic instability in heterogeneous tumors, Journal of theoretical biology 396 (2016) 1–12.
- [12] A. Sottoriva, L. Vermeulen, S. Tavaré, Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors, PLoS Computational Biology 7 (2011) e1001132.
- [13] A. R. Anderson, V. Quaranta, Integrative mathematical oncology, Nature Reviews Cancer 8 (2008) 227.
- [14] J. Jeon, V. Quaranta, P. T. Cummings, An off-lattice hybrid discretecontinuum model of tumor growth and invasion, Biophysical Journal 98 (2010) 37–47.
- [15] Y. Jiao, S. Torquato, Diversity of dynamics and morphologies of invasive solid tumors, AIP advances 2 (2012) 011003.
- [16] R. A. Gatenby, A. S. Silva, R. J. Gillies, B. R. Frieden, Adaptive therapy, Cancer Research 69 (2009) 4894–4903.
- [17] R. A. Gatenby, J. Brown, T. Vincent, Lessons from applied ecology: cancer control using an evolutionary double bind, Cancer research 69 (2009) 7499–7502.
- [18] A. Eladdadi, A. Radunskaya, et al., Modeling cancer-immune responses to therapy, Journal of pharmacokinetics and pharmacodynamics 41 (2014) 461–478.

- [19] F. Frascoli, P. S. Kim, B. D. Hughes, K. A. Landman, A dynamical model of tumour immunotherapy, Mathematical Biosciences 253 (2014) 50–62.
- [20] E. Piretto, M. Delitala, M. Ferraro, Combination therapies and intratumoral competition: insights from mathematical modelling, Journal of Theoretical Biology 446 (2018) 149–159.
- [21] S. Bunimovich-Mendrazitsky, H. Byrne, L. Stone, Mathematical model of pulsed immunotherapy for superficial bladder cancer, Bulletin of Mathematical Biology 70 (2008) 2055–2076.
- [22] A. L. Jenner, C.-O. Yun, A. Yoon, A. C. Coster, P. S. Kim, Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression, Letters in Biomathematics (2018) 1–18.
- [23] N. Bellomo, N. Li, P. K. Maini, On the foundations of cancer modelling: selected topics, speculations, and perspectives, Mathematical Models and Methods in Applied Sciences 18 (2008) 593–646.
- [24] K. P. Wilkie, A review of mathematical models of cancer–immune interactions in the context of tumor dormancy, in: Systems Biology of Tumor Dormancy, Springer, 2013, pp. 201–234.
- [25] R. Eftimie, J. L. Bramson, D. J. Earn, Interactions between the immune system and cancer: a brief review of non-spatial mathematical models, Bulletin of Mathematical Biology 73 (2011) 2–32.
- [26] A. Eladdadi, P. Kim, D. Mallet, Mathematical models of tumorimmune system dynamics, Springer, 2014.
- [27] P. S. Kim, P. P. Lee, Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach, PLoS Computational Biology 8 (2012) e1002742.
- [28] D. M. Catron, A. A. Itano, K. A. Pape, D. L. Mueller, M. K. Jenkins, Visualizing the first 50 hr of the primary immune response to a soluble antigen, Immunity 21 (2004) 341–347.

- [29] H. Mohri, A. S. Perelson, K. Tung, R. M. Ribeiro, B. Ramratnam, M. Markowitz, R. Kost, L. Weinberger, D. Cesar, M. K. Hellerstein, et al., Increased turnover of t lymphocytes in hiv-1 infection and its reduction by antiretroviral therapy, Journal of Experimental Medicine 194 (2001) 1277–1288.
- [30] G. T. Belz, L. Zhang, M. D. Lay, F. Kupresanin, M. P. Davenport, Killer t cells regulate antigen presentation for early expansion of memory, but not naive, cd8+ t cell, Proceedings of the National Academy of Sciences 104 (2007) 6341–6346.
- [31] D. Wodarz, A. R. Thomsen, Effect of the ctl proliferation program on virus dynamics, International Immunology 17 (2005) 1269–1276.
- [32] R. J. De Boer, M. Oprea, R. Antia, K. Murali-Krishna, R. Ahmed, A. S. Perelson, Recruitment times, proliferation, and apoptosis rates during the cd8+ t-cell response to lymphocytic choriomeningitis virus, Journal of Virology 75 (2001) 10663–10669.
- [33] S. M. Kaech, R. Ahmed, Memory cd8+ t cell differentiation: initial antigen encounter triggers a developmental program in naive cells, Nature Immunology 2 (2001) 415.
- [34] R. J. De Boer, D. Homann, A. S. Perelson, Different dynamics of cd4+ and cd8+ t cell responses during and after acute lymphocytic choriomeningitis virus infection, The Journal of Immunology 171 (2003) 3928–3935.
- [35] C. A. Janeway, P. Travers, M. Walport, M. Shlomchik, et al., Immunobiology: the immune system in health and disease, volume 7, Current Biology London, 1996.
- [36] H. Veiga-Fernandes, U. Walter, C. Bourgeois, A. McLean, B. Rocha, Response of naive and memory cd8+ t cells to antigen stimulation in vivo, Nature Immunology 1 (2000) 47.
- [37] M. Ying, B. Pang, Three-dimensional ultrasound measurement of cervical lymph node volume, The British journal of radiology 82 (2009) 617–625.

- [38] D. G. Mallet, L. G. De Pillis, A cellular automata model of tumorimmune system interactions, Journal of Theoretical Biology 239 (2006) 334–350.
- [39] R. Soiffer, F. S. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. Mentzer, M. Jaklitsch, et al., Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviralmediated gene transfer augments antitumor immunity in patients with metastatic melanoma, Journal of Clinical Oncology 21 (2003) 3343–3350.
- [40] R. Soiffer, T. Lynch, M. Mihm, K. Jung, C. Rhuda, J. C. Schmollinger, F. S. Hodi, L. Liebster, P. Lam, S. Mentzer, et al., Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma, Proceedings of the National Academy of Sciences 95 (1998) 13141–13146.
- [41] C. R. Mackay, Chemokine receptors and t cell chemotaxis., Journal of Experimental Medicine 184 (1996) 799–802.
- [42] M. Maurer, E. Von Stebut, Macrophage inflammatory protein-1, The International Journal of Biochemistry & Cell Biology 36 (2004) 1882– 1886.
- [43] A. H. Lin, A model of tumor and lymphocyte interactions, Discrete & Continuous Dynamical Systems-B 4 (2004) 241–266.
- [44] T. Alarcón, H. M. Byrne, P. K. Maini, A cellular automaton model for tumour growth in inhomogeneous environment, Journal of Theoretical Biology 225 (2003) 257–274.
- [45] D. Kirschner, J. C. Panetta, Modeling immunotherapy of the tumorimmune interaction, Journal of mathematical biology 37 (1998) 235– 252.
- [46] T. Kuroishi, S. Tominaga, T. Morimoto, H. Tashiro, S. Itoh, H. Watanabe, M. Fukuda, J. Ota, T. Horino, T. Ishida, et al., Tumor growth rate and prognosis of breast cancer mainly detected by mass screening, Japanese Journal of Cancer Research 81 (1990) 454–462.

- [47] J. Michaelson, S. Satija, R. Moore, G. Weber, E. Halpern, A. Garland, D. B. Kopans, Estimates of breast cancer growth rate and sojourn time from screening database information, Journal of Womens Imaging 5 (2003) 11–19.
- [48] P. Friedl, M. Gunzer, Interaction of t cells with apcs: the serial encounter model, Trends in Immunology 22 (2001) 187–191.
- [49] L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjöblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, et al., The genomic landscapes of human breast and colorectal cancers, Science 318 (2007) 1108–1113.
- [50] H. Hatzikirou, D. Basanta, M. Simon, K. Schaller, A. Deutsch, Go or grow: the key to the emergence of invasion in tumour progression?, Mathematical Medicine and Biology: a Journal of the IMA 29 (2012) 49–65.
- [51] A. M. Mendonsa, T.-Y. Na, B. M. Gumbiner, E-cadherin in contact inhibition and cancer, Oncogene (2018) 1.
- [52] L. L. Brunton, B. A. Chabner, B. C. Knollmann, Therapeutics, MWateria Medica, x887, 60x (2011).
- [53] L. Zitvogel, L. Apetoh, F. Ghiringhelli, G. Kroemer, Immunological aspects of cancer chemotherapy, Nature Reviews Immunology 8 (2008) 59–73.
- [54] S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, M. E. Dudley, Adoptive cell transfer: a clinical path to effective cancer immunotherapy, Nature Reviews Cancer 8 (2008) 299.
- [55] F. Frascoli, E. Flood, P. Kim, A model of the effects of cancer cell motility and cellular adhesion properties on tumour-immune dynamics, Mathematical Medicine and Biology : a journal of the IMA 34 (2017) 215–240.
- [56] A. Sottoriva, J. J. Verhoeff, T. Borovski, S. K. McWeeney, L. Naumov, J. P. Medema, P. M. Sloot, L. Vermeulen, Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity, Cancer Research 70 (2010) 46–56.

- [57] A. Bru, J. Pastor, I. Fernaud, I. Br, S. Melle, C. Berenguer, Super-rough dynamics on tumor growth, Physical Review Letters 81 (1998) 4008– 4011.
- [58] D. Basanta, R. A. Gatenby, A. R. Anderson, Exploiting evolution to treat drug resistance: combination therapy and the double bind, Molecular Pharmaceutics 9 (2012) 914–921.
- [59] R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H.-I. Cho, S. Antonia, S. Altiok, E. Celis, D. I. Gabrilovich, Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice, The Journal of Clinical Investigation 120 (2010) 1111.
- [60] S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al., Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer, Clinical Cancer Research 12 (2006) 878–887.
- [61] M. Greaves, C. C. Maley, Clonal evolution in cancer, Nature 481 (2012) 306–313.
- [62] E. A. Reits, J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K. Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, et al., Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, Journal of Experimental Medicine 203 (2006) 1259– 1271.
- [63] A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, E. M. Lord, Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor, The Journal of Immunology 174 (2005) 7516–7523.
- [64] S. E. Finkelstein, M. Fishman, Clinical opportunities in combining immunotherapy with radiation therapy, Frontiers in Oncology 2 (2012) 169.
- [65] S. E. Finkelstein, C. Iclozan, M. M. Bui, M. J. Cotter, R. Ramakrishnan, J. Ahmed, D. R. Noyes, D. Cheong, R. J. Gonzalez, R. V. Heysek,

et al., Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients, International Journal of Radiation Oncology Biology Physics 82 (2012) 924–932.

- [66] S. E. Finkelstein, R. Timmerman, W. H. McBride, D. Schaue, S. E. Hoffe, C. A. Mantz, G. D. Wilson, The confluence of stereotactic ablative radiotherapy and tumor immunology, Clinical and Developmental Immunology 2011 (2011).
- [67] R. E. Vatner, B. T. Cooper, C. Vanpouille-Box, S. Demaria, S. C. Formenti, Combinations of immunotherapy and radiation in cancer therapy, Frontiers in Oncology 4 (2014) 325.
- [68] S. Demaria, B. Ng, M. L. Devitt, J. S. Babb, N. Kawashima, L. Liebes, S. C. Formenti, Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology Biology Physics 58 (2004) 862–870.
- [69] S. Demaria, E. B. Golden, S. C. Formenti, Role of local radiation therapy in cancer immunotherapy, JAMA oncology 1 (2015) 1325–1332.
- [70] R. A. Burrell, N. McGranahan, J. Bartek, C. Swanton, The causes and consequences of genetic heterogeneity in cancer evolution, Nature 501 (2013) 338–345.
- [71] A. Kusoglu, C. Biray Avci, Cancer stem cells: A brief review of the current status, Gene 681 (2019) 80–85.
- [72] R. K. Jain, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science 307 (2005) 58–62.

 Table 1: Parameters used in the DDE component of the model. For more details about parameter estimation refer to [27]

Par.	Description	Value (range)	Ref.	Notes/comments
$A_0(0)$	Initial concentration of immature APCs	0.01 k/mm ³	[28]	same order of magnitude as the APCs in the lymph node
d_0	Death/turnover rate of immature APCs	$0.03 day^{-1}$	[29]	similar to those of naïve T cells
s _A	Supply rate of imma- ture APCs	$0.3 \mathrm{k/mm^3 day^{-1}}$	[29]	$s_A = A_0(0)d_0$
<i>d</i> ₁	Death/turnover rate of mature APCs	$0.8 \mathrm{day}^{-1}$	[30]	using a half-life of 20 h: $d_1 = (\ln 2)/20 h^{-1}$
K	Equilibrium concen- tration of memory CTLs	$2\% \cdot 200 \text{ k/mm}^3$	[28]	2% of the T-cells in a lymph node of radius 1 mm
r	Logistic growth rate of memory CTLs	log 2 day ⁻¹	[27]	minimum doubling time of 1 day
т	Minimal number of CTL divisions	10	[31]	range from 7 to 17 cell divisions [32, 33]
δ_1	Death/turnover rate of effector CTLS	$0.4 \mathrm{day}^{-1}$	[34]	half-life during T-cell contraction of 41 h: $\delta_1 = (\ln 2)/41$ h ⁻¹
μ	Mass-action coeffi- cient	$(k/mm^3)^{-1}day^{-1}$	[28]	$\mu = 0.5\mu_0 \text{ with } \mu_0 = 4.8\text{cell}^{-1} \text{ day}^{-1} \text{ and } V_{\text{lymph node}} = 8.4 \cdot 10^{-3} \text{ mm}^3$
ρ	Duration of one CTL division	8 h	[35]	T-cell doubles every 8 hours during expansion [34]
σ	Duration of CTL di- vision program	$1+(m-1)\rho$	[36]	first division does not occur un- til 24 hours after stimulation
α	Antigenicity of the tumour	$\frac{10^{-9}}{(k/mm^3)^{-1}}day^{-1}$	[27]	reciprocal of the rate of encoun- tering of antigen from a tumor cell by APC
f	CTLs flow rate out of lymph node to tissue	$0.7 \mathrm{day}^{-1}$	[27]	effector CTLs emigrate at a half- life of 1 day: $f = \ln 2 \text{ day}^{-1}$
V _{ratio}	Ratio of volume of tissue to the lymph node	1000	[37]	lymph node compartment is \sim 1 ml and the breast tissue \sim 1 l

Par.	Description	Value (range)	Ref.	Notes / Comments
Δt	Time step	1 min	[27]	timescale of the fastest dynamic simulated in the model
r	Radius of cells	5 µm	[43]	[38, 44, 28]
T _{div,i}	Avg. division time of i-th cancer phenotype	1-39 day	[45]	[38, 46, 47]
T _o	Avg. division time of <i>origi-</i> <i>nal</i> phenotype	7 day	[45]	[38, 46, 47]
$\sigma_{\rm max}$	Max unit standard devia- tion of CTL diffusion	$\frac{12}{\mu m \min^{-1}}$	[28]	[48]
C _{acc}	CTL acceleration time from 0 to σ_{max}	5 h	[27]	
C _{death}	Avg. CTL lifespan	41 h	[34]	
C _{recruit}	Avg. time fro CTL recruit- ment	22 h	[27]	[39, 40]
C _{kill}	Avg. time fro CTL to kill tumour cell	24 h	[27]	killing target cells may require a long recovery period
R	Radius of region of interest	620.4 µm	[27]	
h	Thickness of CTL cloud	$3\sigma_{\max}\sqrt{\Delta t}$	[27]	probability that a CTL could pass from outside into the region of in- terest is 0.001
P _{mut}	Probability of mutation	$0.01 \ min^{-1/2}$	[49]	
P _{recog,i}	Probability of recognition of i-th cancer phenotype	0-1		spans the entire probability range
Po	Probability of recognition of <i>original</i> phenotype	1		the APC cell can always recognize the antigen released

 Table 2: Parameters used in the ABM component of the model. For more details about parameter estimation refer to [27]

Name	Description	Precog	T _{div}
	First metastatic breast cancer clone	1 min^{-1}	7 day
original	that colonises the new tissue, with		
	evolutionary potential of phenotypic mutations.		
	Clone proliferates at the same rate of the <i>original</i>		
(0.5,0.5)	clone, but has an increased ability to hide from	$0.5 { m min}^{-1}$	7 day
	the immune system.		
	Clone is not recognised by CTLs, but		13 day
(0,1)	the evolutionary cost of its ability is	$0 \min^{-1}$	
(0,1)	paid in term of proliferation: this	0 11111	
	phenotype is the slowest to reproduce.		
(0.25,0.75)	Clone has intermediate properties:	$0.25 \mathrm{~min^{-1}}$	10 day
(0.25,0.75)	strong ability to hide and slow proliferation		
(0.75,0.25)	Clone has intermediate properties:	$0.75 \mathrm{~min^{-1}}$	4 day
(0.75,0.25)	weak ability to hide and fast proliferation		
	Clone has the ability to reach		
(1,0)	high number of cellular duplication, but is	$1 \min^{-1}$	1 day
	always recognised by the immune system.		

Table 3: Cancer clonal composition

Table 4: **Parameters used to model therapies**. Ranges indicate that different therapies (single and combined) are simulated with different values.

Parameter	Description	Value (range)
Ch _{time}	Duration of a chemotherapy cycle	10-50 day
$Ch_{\rm eff}$	Effect of chemotherapy	0 - 1/4
Bo _{time}	Persistence time of boosting (TIL)	3 day
Bo _{eff}	Number of CTL cells injected	500-1000